Literature DB >> 15812565

A new CARD15 mutation in Blau syndrome.

Marjan M van Duist1, Mario Albrecht, Marta Podswiadek, Daniela Giachino, Thomas Lengauer, Leonardo Punzi, Mario De Marchi.   

Abstract

The caspase recruitment domain gene CARD15/NOD2, encoding a cellular receptor involved in an NF-kappaB-mediated pathway of innate immunity, was first identified as a major susceptibility gene for Crohn's disease (CD), and more recently, as responsible for Blau syndrome (BS), a rare autosomal-dominant trait characterized by arthritis, uveitis, skin rash and granulomatous inflammation. While CARD15 variants associated with CD are located within or near the C-terminal leucine-rich repeat domain and cause decreased NF-kappaB activation, BS mutations affect the central nucleotide-binding NACHT domain and result in increased NF-kappaB activation. In an Italian family with BS, we detected a novel mutation E383K, whose pathogenicity is strongly supported by cosegregation with the disease in the family and absence in controls, and by the evolutionary conservation and structural role of the affected glutamate close to the Walker B motif of the nucleotide-binding site in the NACHT domain. Interestingly, substitutions at corresponding positions in another NACHT family member cause similar autoinflammatory phenotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812565     DOI: 10.1038/sj.ejhg.5201404

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  20 in total

Review 1.  Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation.

Authors:  L Ferrero-Miliani; O H Nielsen; P S Andersen; S E Girardin
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 2.  NLR proteins: integral members of innate immunity and mediators of inflammatory diseases.

Authors:  Jeanette M Wilmanski; Tanja Petnicki-Ocwieja; Koichi S Kobayashi
Journal:  J Leukoc Biol       Date:  2007-09-17       Impact factor: 4.962

Review 3.  The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation.

Authors:  Ivan Tattoli; Leonardo H Travassos; Leticia A Carneiro; Joao G Magalhaes; Stephen E Girardin
Journal:  Semin Immunopathol       Date:  2007-08-10       Impact factor: 9.623

Review 4.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 5.  NOD proteins: regulators of inflammation in health and disease.

Authors:  Dana J Philpott; Matthew T Sorbara; Susan J Robertson; Kenneth Croitoru; Stephen E Girardin
Journal:  Nat Rev Immunol       Date:  2013-12-13       Impact factor: 53.106

Review 6.  New insights into gastrointestinal and hepatic granulomatous disorders.

Authors:  Majid A Almadi; Abdulrahman M Aljebreen; Faisal M Sanai; Victoria Marcus; Ebtissam S Almeghaiseeb; Subrata Ghosh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-05       Impact factor: 46.802

Review 7.  NLRs in immune privileged sites.

Authors:  Holly L Rosenzweig; Stephen R Planck; James T Rosenbaum
Journal:  Curr Opin Pharmacol       Date:  2011-07-29       Impact factor: 5.547

8.  Co-existence of chronic renal failure, renal clear cell carcinoma, and Blau syndrome.

Authors:  Ipek Akil; Aykan Ozguven; Ebru Canda; Omer Yilmaz; Nalan Nese; Mine Ozkol; Sandra May; Andre Franke; Sebahattin Cirak
Journal:  Pediatr Nephrol       Date:  2010-05       Impact factor: 3.714

9.  NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis.

Authors:  Holly L Rosenzweig; Tammy M Martin; Monica M Jann; Stephen R Planck; Michael P Davey; Koichi Kobayashi; Richard A Flavell; James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

Review 10.  NOD-like receptors and inflammation.

Authors:  Rebeccah J Mathews; Michael B Sprakes; Michael F McDermott
Journal:  Arthritis Res Ther       Date:  2008-11-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.